Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
A universal oncolytic virus boost of chimeric antigen receptor tumour-infiltrating lymphocytes in adoptive T cell therapies
EF 2022-23
Résumé
Creating a universal-prime boost strategy using multi-specific T cells taken from the tumour infiltrating lymphocyte (TILs) population can increase the success of adoptive T cell therapies (ACT). As a personalized living-drug, ACT is a last resort treatment due to the extensive time, cost and labour involved for each patient, making it inaccessible. Oncolytic virus (OV) vaccines, encoding a personalized tumour-associated antigen (TAA) have been proven as potent boosting agent for ACT. This combination of ACT and OV vaccines have proven successful in (1) promoting T cell proliferation in-vivo and (2) inducing immune infiltration to the solid tumour microenvironment. TILs offer a plethora of TAA specific T-cell receptors (TCRs) when they can be successfully isolated and expanded. Chimeric antigen receptors (CARs) can be engineered into TILs and can recognize any specific antigen, including a matched antigen in an OV vaccine. We have previously validated combining ACT with an OV vaccine “boost” through a CAR-OV interaction to promote in-vivo expansion of naïve splenocytes. I propose to isolate TILs, engineer them with a CAR matched to an OV vaccine and boost TILs in-vivo to proliferate a polyclonal T cell population with TAA-specific TCRs. Using synergetic murine models, I will develop protocols for TIL isolation, culture, and CAR-engineering for OV-mediated ACT boost in-vivo. Uniting a universal OV vaccine with a matched universal CAR creates an “off the shelf” combination where any TIL product can be engineered, lowering the resource burden of traditional ACT, and allowing it to become more accessible to all cancer types.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
490912
Name
Morris Claire G
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A universal oncolytic virus boost of chimeric antigen receptor tumour-infiltrating lymphocytes in adoptive T cell therapies
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adoptive Cell Therapy; Cancer; Cell Signalling; Chimeric Antigen Receptors; Cytokines; Immunology; Molecular Biology; Murine Model; Oncolytic Virus Vaccines; T Cells
Abstract
Creating a universal-prime boost strategy using multi-specific T cells taken from the tumour infiltrating lymphocyte (TILs) population can increase the success of adoptive T cell therapies (ACT). As a personalized living-drug, ACT is a last resort treatment due to the extensive time, cost and labour involved for each patient, making it inaccessible. Oncolytic virus (OV) vaccines, encoding a personalized tumour-associated antigen (TAA) have been proven as potent boosting agent for ACT. This combination of ACT and OV vaccines have proven successful in (1) promoting T cell proliferation in-vivo and (2) inducing immune infiltration to the solid tumour microenvironment. TILs offer a plethora of TAA specific T-cell receptors (TCRs) when they can be successfully isolated and expanded. Chimeric antigen receptors (CARs) can be engineered into TILs and can recognize any specific antigen, including a matched antigen in an OV vaccine. We have previously validated combining ACT with an OV vaccine “boost” through a CAR-OV interaction to promote in-vivo expansion of naïve splenocytes. I propose to isolate TILs, engineer them with a CAR matched to an OV vaccine and boost TILs in-vivo to proliferate a polyclonal T cell population with TAA-specific TCRs. Using synergetic murine models, I will develop protocols for TIL isolation, culture, and CAR-engineering for OV-mediated ACT boost in-vivo. Uniting a universal OV vaccine with a matched universal CAR creates an “off the shelf” combination where any TIL product can be engineered, lowering the resource burden of traditional ACT, and allowing it to become more accessible to all cancer types.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Morris, Claire G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~